Evidence map›Paper›PMID 33934828›Full record

ReviewAdvances in virus research2021

Proteomic approaches to investigate gammaherpesvirus biology and associated tumorigenesis.

Danielle L Chappell, Maria C White, Blossom Damania

Open access · greenAbstract readReview
In one paragraph

Review in Advances in virus research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 70% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Danielle L ChappellLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Maria C WhiteLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Blossom DamaniaLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States. Electronic address: blossom_damania@med.unc.edu.
University of North Carolina at Chapel Hill · US

Funding

Vironomics and Biostatistics CoreP01CA019014 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BLOSSOM A DAMANIA, NANCY JOAN RAAB-TRAUB · 1985 to 2026
$43.8M
Integrated Training in Cancer Model SystemsT32CA009156 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 1985 to 2020
$19.7M
The road to recovery: An assessment of patient-reported quality of life among cancer survivors in Malawi.U54CA254564 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI OLSHAN, ANDREW · 2020 to 2024
$6.1M
Role of KSHV Viral Proteins in Signaling and PathogenesisR01CA096500 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAMANIA, BLOSSOM A · 2002 to 2022
$6.0M
Targeted Therapies for HIV-Associated Kaposi Sarcoma and LymphomaR01CA163217 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BLOSSOM A DAMANIA, Dirk P Dittmer · 2011 to 2026
$5.5M
Mechanisms of KSHV TransmissionR01CA239583 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAMANIA, BLOSSOM A, DITTMER, DIRK P · 2019 to 2023
$2.8M
Modulation of Innate Immunity by KSHVR01DE028211 · NIDCR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAMANIA, BLOSSOM A · 2018 to 2022
$2.1M
Impact of HIV on the Tumor MicroenvironmentR01CA228172 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAMANIA, BLOSSOM A, DITTMER, DIRK P · 2018 to 2022
$2.0M
NCI NIH HHS P01 CA019014NCI NIH HHS R01 CA096500NCI NIH HHS R01 CA163217NCI NIH HHS R01 CA228172NCI NIH HHS R01 CA239583NCI NIH HHS T32 CA009156NCI NIH HHS U54 CA254564NIDCR NIH HHS R01 DE028211
6 · The paper itself

Abstract

The DNA viruses, Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV), are members of the gammaherpesvirus subfamily, a group of viruses whose infection is associated with multiple malignancies, including cancer. The primary host for these viruses is humans and, like all herpesviruses, infection with these pathogens is lifelong. Due to the persistence of gammaherpesvirus infection and the potential for cancer formation in infected individuals, there is a driving need to understand not only the biology of these viruses and how they remain undetected in host cells but also the mechanism(s) by which tumorigenesis occurs. One of the methods that has provided much insight into these processes is proteomics. Proteomics is the study of all the proteins that are encoded by a genome and allows for (i) identification of existing and novel proteins derived from a given genome, (ii) interrogation of protein-protein interactions within a system, and (iii) discovery of druggable targets for the treatment of malignancies. In this chapter, we explore how proteomics has contributed to our current understanding of gammaherpesvirus biology and their oncogenic processes, as well as the clinical applications of proteomics for the detection and treatment of gammaherpesvirus-associated cancers.

Indexed as

CarcinogenesisHost Microbial InteractionsBooksDNA VirusesGammaherpesvirinaeHerpesviridae InfectionsHumansProteomicsTumor Virus InfectionsVirus ReplicationEBVHerpesvirusKSHVOncogenicProteomicsVirus-host interactions

Identifiers

PMID33934828
PMCPMC8127003
OpenAlexW3106462111

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.